Stock Ratings / Health Care / CCEL / options

PARK (49) NIVF (22) MGRX (34) VMD (69) ⌘ Pro Terminal →

Cryo-Cell International Inc. (CCEL) Options Positioning, Max Pain & Unusual Sweeps

$5.19 +1.17% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.19

Cryo-Cell International Inc. (CCEL) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY) →

ROARABLE C • HOLD / WATCH Cap $41.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.19 (+0.02%)🧬 Cannibal Buyback (-1.52% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 0.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY • 55.2% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CCEL)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (64/100 Composite)

🔍 WHY CCEL SCORES 64/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+17/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 0.1% FCF Margin ($5.2M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: Macro Regime Fit+15/20 pts (23% of score)

FRED Regime × Technicals: 90% of 52W Range • RSI-14 at 64.3 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$4.36+1.4% Next Q

Q2 (-2Q)

Grade C$4.42+0.9% Next Q

Q3 (-1Q)

Grade C$4.46+16.4% Next Q

Current

Grade C$5.19+1.1% Hist 90D α

Trajectory: C (56) → C (64)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CCEL Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 64/100 (C) score, CCEL faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.52% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($4.31) or 200D SMA ($3.68) invalidates the momentum regime and cuts Target Base ($5.33) toward Bear Floor ($4.16).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CCEL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CCEL Beats Next Quarter EPS Consensus (Nov 29, 2026) & Holds Above 200D SMA”

YES 64%NO 36%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (CCEL)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for CCEL.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating CCEL & AI Leaders Without Chasing Tops

✓Institutional whale strikes & implied earnings move audit on CCEL
✓How disciplined traders manage risk using pre-published trigger & invalidation levels
✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CCEL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +51.75%▲ ASCENDING CHANNEL

2026-10-30O $5.10H $5.21L $5.00C $5.19VOL 12.0K

RES: $5.61SUP: $3.55SMA50: $4.31SMA200: $3.68

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CCEL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CCEL Butterfly Map → + Track CCEL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

48.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CCEL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CCEL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CCEL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CCEL)

Health Care Rank #147 of 1016 ⚔️ PARK vs CCEL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CCEL vs. PARK, NIVF, MGRX, VMD)

Industry: Misc Health and Biotechnology Services (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cryo-Cell International Inc. (CCEL) ranks #147 by composite RQD confidence (64/100, grade C) and #770 by equity capitalization ($41.8M). Within this direct 5-issuer industry benchmark cohort, VMD leads on earnings valuation at 24.6x trailing P/E, while CCEL leads on capital efficiency and profitability with 18.2% ROIC and — gross margin. VMD currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with CCEL at 64/100 (C).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CCEL ACTIVE Cryo-Cell International Inc.	C	64/100	—	—	18.2%	+1.17%	$41.8M	Benchmark Subject
PARK Park Dental Partners Inc.	D	49/100	—	—	—	-2.79%	$95.4M	/park-vs-ccel →
NIVF NewGenIvf Group Limited (Class A)	E	22/100	—	—	-32.8%	-5.00%	$11.3M	/nivf-vs-ccel →
MGRX Mangoceuticals Inc.	E	34/100	—	54.9%	-35.0%	-1.47%	$5.7M	/mgrx-vs-ccel →
VMD Viemed Healthcare Inc.	C+	69/100	24.6x	57.5%	13.0%	-0.40%	$379.0M	/vmd-vs-ccel →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-11-30 • CIK 0000862692

In its most recent audited fiscal period (FY2025, filed 2025-11-30), Cryo-Cell International Inc. (CCEL) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$2.4M, operating cash flow of $5.5M, and free cash flow of $5.2M (+45.5% YoY). On the balance sheet, CCEL closed FY2025 with $61.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-11-30	$0	-$2.4M	$5.5M	$5.2M	$61.7M	—
FY2024 (FY)	2024-11-30	$0	$402.0K	$6.0M	$3.6M	$64.7M	—
FY2023 (FY)	2023-11-30	$0	-$9.5M	$8.9M	$8.9M	—	—

3. CCEL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CCEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Cryo-Cell International Inc. (NYSE: CCEL) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $5.19 (+1.17% 1D, market cap $41.8M). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 13/20. Across 1016 tracked Health Care issuers, CCEL ranks #147 in composite RQD confidence.

How does CCEL compare to PARK and NIVF in the Health Care sector?

Within the Health Care sector (Misc Health and Biotechnology Services), CCEL carries a Roarable C (64/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 18.2%. By comparison, PARK (Park Dental Partners Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC —, cap $95.4M) and NIVF (NewGenIvf Group Limited (Class A)) posts a E grade (22/100 RQD, P/E N/A, ROIC -32.8%, cap $11.3M). Among the 5-stock peer group, VMD leads on earnings multiple (24.6x) while CCEL leads on capital efficiency (18.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CCEL?

Per CCEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-11-30, CIK 0000862692), Cryo-Cell International Inc. generated $0 in revenue, -$2.4M in net income, and $5.2M in free cash flow against $61.7M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CCEL trading relative to its 50-day, 200-day, and 52-week technical levels?

CCEL last traded at $5.19 (+1.17% on volume of 8,072 shares), positioning the stock +20.42% above its 50-day simple moving average ($4.31) and +41.03% above its 200-day simple moving average ($3.68). Across its 52-week range of $2.72 to $5.45, CCEL sits at the 90.5% percentile with a 14-day RSI of 64.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($4.54 to $5.84).

CCEL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is CCEL's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for CCEL.

Direct Sub-Reports: CCEL RQD Cockpit CCEL 12M Forecast CCEL Earnings & Move CCEL Dividends & DRIP CCEL Insiders & 13F CCEL Whale Options CCEL Profit Sankey CCEL News & Why